MyMD Pharmaceuticals' Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell StudyBusiness Wire • 08/05/21
MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and DermatitisBusiness Wire • 07/27/21
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1Business Wire • 07/07/21
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory BoardBusiness Wire • 05/17/21
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals' Supera-CBD at the 3rd Annual Neuroimmunology Drug Development SummitBusiness Wire • 04/28/21
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid CompoundsBusiness Wire • 04/22/21
MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Know as Shares SurgeInvestorPlace • 04/20/21
